Perrigo Company plc

Perrigo Company plc (PRGO) Market Cap

Perrigo Company plc has a market capitalization of $1.62B.

Financials based on reported quarter end 2025-12-31

Price: $11.80

0.38 (3.33%)

Market Cap: 1.62B

NYSE · time unavailable

CEO: Patrick Lockwood-Taylor

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

IPO Date: 1991-12-17

Website: https://www.perrigo.com

Perrigo Company plc (PRGO) - Company Information

Market Cap: 1.62B · Sector: Healthcare

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Analyst Sentiment

67%
Buy

Based on 5 ratings

Analyst 1Y Forecast: $27.67

Average target (based on 3 sources)

Consensus Price Target

Low

$20

Median

$22

High

$23

Average

$22

Potential Upside: 82.2%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PERRIGO PLC (PRGO) — Investment Overview

🧩 Business Model Overview

Perrigo plc (PRGO) is a leading global provider of over-the-counter (OTC) healthcare and wellness products. The company operates as a manufacturer and distributor of consumer self-care products, focusing on affordable, high-quality alternatives to branded medications and personal care solutions. Perrigo’s operations are structured around two main segments: Consumer Self-Care Americas and Consumer Self-Care International, encompassing a diverse portfolio of OTC medicines, nutritional products, and consumer health items available in retail, pharmacy, and e-commerce channels. Through organic development, selective acquisitions, and partnerships, Perrigo aims to provide consumers with both value and trust in its product offerings, positioning itself at the intersection of cost-conscious healthcare and growing self-care awareness.

💰 Revenue Streams & Monetisation Model

Perrigo generates revenue primarily through the manufacture and sale of self-care consumer products. These include OTC pharmaceuticals, infant and adult nutrition, dietary supplements, and personal care items such as skin care and oral hygiene products. The company’s monetisation model leverages large-scale relationships with major retailers, pharmacies, and e-commerce platforms, supplying both store-branded (“private label”) and Perrigo’s own branded products. The firm’s private label business, where it supplies products that retailers sell under their own brands, remains a core revenue driver—especially in segments such as analgesics, allergy relief, lifestyle medications (e.g., smoking cessation), and gastrointestinal care. Perrigo also invests in developing and acquiring established brands to generate incremental value from direct-to-consumer marketing and global distribution. International operations further diversify revenue, tapping into European, Asia-Pacific, and other markets through localized product offerings and partnerships.

🧠 Competitive Advantages & Market Positioning

Perrigo's primary competitive advantage lies in its cost-efficient manufacturing capabilities and expertise in developing generic OTC solutions that compete directly with higher-priced branded products. Its ability to deliver quality, regulatory-compliant goods at lower costs enables retail partners to compete aggressively on price while maintaining margins. The company benefits from longstanding relationships with major retail chains and a reputation for reliability, which grant it significant shelf space and recurring volumes. Perrigo’s broad product portfolio across many therapeutic and wellness categories provides resilience against single-product risks and enhances its negotiating leverage with suppliers and distributors. A notable strategic moat is the company’s focus on store-brand (private label) offerings, which enjoy tailwinds from growing consumer acceptance of private labels and the ongoing drive among retailers to expand their own brands. Regulatory expertise, including a track record of product approvals and compliance across geographies, further bolsters Perrigo's market position relative to potential new entrants.

🚀 Multi-Year Growth Drivers

Several secular and company-specific trends are poised to support Perrigo’s growth over the long term: - **Increasing Self-Care and Preventive Health Awareness:** As consumers take more control over their health and wellness, demand for accessible OTC solutions continues to expand globally. - **Retailer Focus on Private Labels:** Retailer efforts to broaden their private label offerings support Perrigo’s core revenue stream, as stores look to improve margins and foster consumer loyalty. - **Expansion into Adjacent Categories:** The company’s ability to innovate and extend existing platform technologies into adjacent self-care, nutrition, and personal care categories opens new growth avenues. - **International Market Penetration:** Emerging markets and under-penetrated regions offer room for expansion via new product launches, partnerships, and localized brand strategies. - **Strategic M&A:** Perrigo has a history of accretive acquisitions and continues to seek synergistic opportunities, aiming to expand its brand portfolio and geographic footprint. - **E-commerce Channel Growth:** Shifting consumer purchasing patterns toward online channels position Perrigo to capitalize further through direct-to-consumer initiatives and digital partnerships.

⚠ Risk Factors to Monitor

Investors should remain cognizant of the following key risks: - **Generic Product Margin Compression:** The commoditized nature of private label and generic OTC products could compress margins in the event of increased price competition among manufacturers. - **Regulatory Landscape:** As a producer of health-related products, Perrigo is exposed to evolving regulations, recalls, and quality control scrutiny across multiple markets; regulatory delays or compliance failures can impact revenue and reputation. - **Concentration Risk:** Heavy reliance on key retail customers and certain large contracts may expose revenue to renegotiation or channel disruption. - **Supply Chain Vulnerabilities:** Perrigo’s complex manufacturing and distribution networks can be susceptible to supply chain interruptions, raw material cost inflation, or geopolitical trade risks. - **Litigation and Product Liability:** Given the nature of the company’s products, Perrigo is subject to legal risks arising from product recalls, adverse health events, or patent disputes. - **Currency Fluctuations:** As a global company, Perrigo’s financials may be sensitive to changes in exchange rates, particularly given its exposure to European and other international markets.

📊 Valuation & Market View

Perrigo’s valuation typically reflects its predictable cash flow generation and defensive industry profile, balanced against the mature, competitive, and sometimes margin-constrained landscape of generic OTC healthcare. Market sentiment tends to price in stability on the back of recurring revenue from large retail contracts and widespread consumer adoption of private label products. However, growth multiples may remain capped by comparatively modest organic growth rates, ongoing integration risks from acquisitions, and evolving regulatory headwinds. The investment community often evaluates Perrigo on metrics such as enterprise value-to-EBITDA, price-to-earnings, and free cash flow yield relative to peers in the consumer health and generic pharmaceutical segments. Long-term growth potential and downside protection are key factors analysts consider, with a keen eye on execution in new product launches, international expansion, and margin management.

🔍 Investment Takeaway

Perrigo plc stands as a significant player in the OTC healthcare and consumer self-care market, underpinned by its strengths in cost-efficient manufacturing, wide distribution, and private label leadership. Its diversified product mix and global reach provide a level of resilience uncommon in the sector, helping buffer against isolated market or product shocks. The company’s growth prospects are fueled by enduring consumer and retail trends toward self-care and private-label products, supported by strategic moves into adjacent categories and international markets. However, investors must weigh the company’s defensive attributes against potential headwinds such as intensifying price competition, regulatory unpredictability, and reliance on a handful of major retail partners. For a long-term, risk-tolerant investor seeking exposure to the stable but evolving consumer health sector, Perrigo offers a solid, cash-generative proposition with the potential for moderate growth and further operational improvements. Continuous monitoring of regulatory developments, competitive dynamics, and execution on growth strategies remains essential for a sustained investment thesis.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"For Q4 2025, PRGO reported revenue of $1.11 billion and a net income loss of $1.42 billion, translating to an EPS of -$10.23. Despite negative net income, the company generated a free cash flow of $148.6 million, supported by operating cash flow of $175.4 million and capital expenditure of $26.8 million. The balance sheet shows a solid net cash position, with total assets at $8.54 billion against liabilities of $5.6 billion, resulting in a net debt of -$495 million. Quarterly dividends were maintained at $0.29 per share, with a 1-year price target consensus at $21.5. PRGO shows resilience in cash generation amid substantial losses due to likely one-off expenses or adjustments. The company has no recent debt or equity financing, indicating a stable capital structure, though insufficient profitability impacts valuation attractiveness. Analyst sentiment remains cautious with targeted stock prices suggesting modest upside potential. Continuing dividends underscore a commitment to shareholder returns despite financial challenges."

Revenue Growth

Neutral

Revenues for the quarter reached $1.11 billion, indicating stable core business performance, though growth catalysts are unclear.

Profitability

Neutral

Reported a substantial net loss of $1.42 billion with negative EPS, impacting operational efficiency and highlighting profitability issues.

Cash Flow Quality

Positive

Solid free cash flow of $148.6 million, strong operating cash, and consistent dividend payouts highlight good liquidity management.

Leverage & Balance Sheet

Good

A strong net cash position with total equity of $2.94 billion provides financial stability and resilience against liabilities.

Shareholder Returns

Neutral

Consistent dividend payments demonstrate a focus on returning value to shareholders amid earnings challenges.

Analyst Sentiment & Valuation

Caution

Valuation metrics suggest limited upside, with analyst targets indicating cautious market expectations given current financials.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management framed 2025 as a turnaround year (share gains, retailer distribution wins, and $320M benefits from Project Energize/supply chain reinvention), but Q&A pressure centered on whether 2026 guidance is “fixable” given macro softness and under-absorption. Patrick emphasized that OTC weakness is largely transitory (~90% of the decline driven by trade-down/unit size and lack of historical price increases) and argued 2H should normalize as innovation (~60% value), geographic expansion (~65%), distribution gains (>50%), and demand generation (~2/3) land in the second half. However, Eduardo’s guidance embeds the key hurdle: plant under-absorption creates a ~$0.60 EPS headwind to CORE in 2026, expected to recover into 2027. Liquidity/deleveraging relies on Dermacosmetics proceeds early Q2 to reduce debt, while strategic review of Infant Formula remains ongoing with potential additional noncash impairments up to $350M in 1Q 2026 and significant working capital tied to inventory.

AI IconGrowth Catalysts

  • Accelerated OTC store brand share gains throughout 2025 after years of decline (CORE organic net sales down, but share gains reversed declines)
  • Deepened retailer partnerships with demand-generation capabilities; management cited over $100M in new distribution and competitive takeaways
  • Innovation pipeline tripled in value vs prior year (about 60% of innovation/value expected in 2H 2026 per commentary)
  • Supply stabilization in infant formula: service levels recovered to above 90% (while demand recovery slowed vs competition)

Business Development

  • Dermacosmetics business announced divestiture expected to close in Q2 2026 pending final antitrust clearance (proceeds planned for debt reduction)
  • Ongoing Infant Formula strategic review: working with advisers to evaluate optimize operations, potential partnerships, and potential divestments
  • Retailer-driven store brand OTC demand generation (no single retailer named, but described as top customers with major timing in 2H)

AI IconFinancial Highlights

  • FY 2025 All-In: operating income +2%, EPS +7% to $2.75; finished in line with revised guidance
  • FY 2025 CORE Perrigo: operating income +7%; core EPS +14%
  • Q4 2025 CORE: organic net sales -2% (despite strong share gains); CORE operating income -$4M (-2%); CORE EPS $0.76 (-$0.02)
  • 2026 CORE outlook: organic net sales -3.5% to +0.5%; CORE gross margin 39%–40%; CORE operating margin 15%–16%; CORE EPS $2.25–$2.55
  • 2026 All-In outlook (includes Infant Formula; assumes Dermacosmetics divestiture in 2Q): net sales -5.5% to -1.5%; gross margin 36.5%–37.5%; operating margin 12.5%–13.5%; EPS $2.00–$2.30
  • 2H 2026 phasing: CORE EPS ~30%–35% in 1H and 65%–70% in 2H (modestly above typical pattern)
  • Temporary under-absorption impact to all CORE Perrigo EPS in 2026 of approx. $0.60 (management expects recovery into 2027)
  • Margin trend cited: OI margin expanded by 230 bps over past 2.5 years; net leverage down from 5.5x to 4.0x
  • FY 2025 GAAP: goodwill impairment charge of $1.3B; potential additional noncash goodwill impairments up to $350M in 1Q 2026 due to goodwill reallocation to new reporting units

AI IconCapital Funding

  • Cash at 12/31/2025: $532M
  • Operating cash flow: $175M in Q4; $239M for full year 2025
  • Net leverage ratio: ~4.0x (slightly above updated projection due to FX translation on gross debt and lower year-end cash)
  • Dividend: held (amount not specified); continued commitment while assessing sustainable return
  • Dermacosmetics sale proceeds planned for debt reduction in early Q2 2026

AI IconStrategy & Ops

  • Operational enhancement program (new 2-year initiative): global workforce reduction ~7%
  • Annualized pretax savings targeted: $80M–$100M (approx. 80% expected in 2026)
  • Total cost to achieve savings: $80M–$90M
  • Operational levers described: evolve structure for agility, accelerate decision-making, better leverage technology; supply chain and distribution network cost reduction focus
  • Project Energize and supply chain reinvention delivered $320M in benefits in 2025
  • Cost model pressures: temporary OTC plans under-absorption; advertising/promotion higher costs and reset of variable incentive plans

AI IconMarket Outlook

  • U.S. OTC consumption: sales down 5.1% over last 13 weeks vs prior year; compared with 4.3% decline in Q4 2025 and 1.2% decline for full-year 2025
  • Expectation that OTC market consumption remains negative in 1H 2026; 2H improvement driven by normalization (catch up to missed value, absence of further value erosion assumed)
  • Management confidence drivers for 2H 2026: ~60% of innovation value in 2H; ~65% of opportunistic geographic expansion in 2H; >50% of competitive takeaway/distribution gains in 2H; ~2/3 of demand generation landing in 2H

AI IconRisks & Headwinds

  • Infant Formula remains a structural challenge impacting financials and 2026 outlook; All-In results assume normalization actions but still include significant EPS pressure
  • Working capital strain from Infant Formula inventory build: inventory levels built ahead of a planned 2H share gain did not materialize as expected; inventory depletion expected to normalize working capital vs prior years
  • Temporary EPS drag from plant under-absorption: approx. $0.60 unfavorable to CORE in 2026 (expected recovery in 2027)
  • OTC category headwinds: transitory market dynamics cited as ~90% of OTC declines including trade-down to smaller units, rollbacks from national brands, and less price increase than historically seen
  • Q1 2026 additional noncash impairment risk: goodwill reallocation to new reporting units may trigger additional impairment charges up to $350M
  • Liquidity/FX leverage risk: net leverage ~4.0x slightly above projection due to currency translation on gross debt and lower cash balances

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the PRGO Q4 2025 (reported 2026-02-26) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PRGO)

© 2026 Stock Market Info — Perrigo Company plc (PRGO) Financial Profile